1. Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J. Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies: a population-based study from northern Sweden. Acta Oncol 2016;55:91–98.
2. Owen RG. Developing diagnostic criteria in Waldenstrom’s macroglobulinemia. Semin Oncol 2003;30:196–200.
3. Bufalino SB, Patel MM, Kruczek KR, et al. Disease characteristics, treatment patterns, and patient outcomes of lymphoplasmacytic lymphoma or Waldenstroms macroglobulinemia: a single institution retrospective review. Blood 2016;128:5341.
4. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30:116–120.
6. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med 2018;378:2399–2410.
7. Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E. Prognostic factors and primary treatment for Waldenström macroglobulinemia: a Swedish Lymphoma Registry study. Br J Haematol 2018;183:564–577.
10. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133:158–164.
11. Morel P, Monconduit M, Jacomy D, et al. Patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000;96:852–858.
13. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood 2006;107:3442–3446.
19. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as firstline treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
21. Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. J Pathol Transl Med 2011;45:254–260.
24. Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol 2016;29:241–248.
25. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
26. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 2012;367:826–833.
27. Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol 2018;180:374–380.
28. Abeykoon JP, Paludo J, King RL, et al. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. Am J Hematol 2018;93:187–194.
29. Poulain S, Roumier C, Bertrand E, et al. TP53 mutation and its prognostic significance in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2017;23:6325–6335.
30. Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, signaling, and treatment of Waldenström macroglobulinemia. J Clin Oncol 2017;35:994–1001.